Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Paradigm Biopharmaceuticals ( (AU:PAR) ).
Paradigm Biopharmaceuticals has achieved significant milestones in its phase 3 clinical trial for knee osteoarthritis treatment with iPPS. The company activated its first Australian clinical site and received consent from the first Australian patient, marking the start of patient enrollment. With 11 sites in Australia and 48 in the US preparing for activation, Paradigm is on track with its global development timeline. This progress underscores the company’s operational achievements and engagement with leading clinical investigators, potentially enhancing its market position in addressing unmet medical needs.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd. is a late-stage drug development company focused on improving patients’ health and quality of life by developing pharmaceutical therapies. The company is currently concentrating on developing injectable pentosan polysulfate sodium (iPPS) for treating diseases characterized by inflammation, such as osteoarthritis and mucopolysaccharidosis.
YTD Price Performance: -14.67%
Average Trading Volume: 971,399
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$124.6M
See more insights into PAR stock on TipRanks’ Stock Analysis page.